Arroyo BioSciences, LLC is a biotechnology company founded in 2010 by Dr. Rolf Swenson. The Company is committed to drug discovery of new agents for the treatment of fibrosis via the novel sphingosine-1-phosphate signaling pathway.
- Focused on the research, development and commercialization of first in class drugs for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic disorders.
- Discovered proprietary potent and selective sphingosine 1 phosphate receptor 2 (S1P2) antagonist compounds with antifibrotic activity.
- AB22 identified as a lead candidate with low toxicity and good pharmacokinetics.
- Potential for development of first-in-class, first line therapeutics for the treatment of multiple fibroproliferative diseases
Idiopathic Pulmonary Fibrosis | Pulmonary Hypertension | Liver, Kidney Disease
Cardiovascular Disease | Scleroderma | Glaucoma